CCI clears Advent International's Rs 3,150 crore investment in Yatharth Hospital

Advent International has officially secured the green light from the Competition Commission of India to channel an impressive Rs 3,150 crore into Yatharth Hospitals through its affiliate, Rasmalai Limited. Post-investment, Advent will own a 24.9 percent minority stake in the healthcare entity, which is poised to leverage this financial boost for its expansion efforts and enhancing its healthcare network amidst a backdrop of thriving operational revenues and profit growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ogpiknU
via IFTTT

Read More

Pharma industry steps up API investments to cut import dependence, move up value chain

India's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Investments in active pharmaceutical ingredients and advanced therapies are on the rise to meet new healthcare demands. Industry leaders highlight the significance of supply-chain resilience and advancements in manufacturing capabilities. Recent data indicates strong domestic market growth and increasing pharmaceutical exports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hX7HyBe
via IFTTT

Read More

The man behind Lord’s Mark: Dr. Sachidanand Upadhyay features in TIME Magazine for the third consecutive year

Dr. Sachidanand Upadhyay has gained recognition from TIME Magazine for his remarkable contributions to technology and innovation. Lord’s Mark Industries Limited is spearheading key projects in healthcare, defence, and sustainability. With critical product registrations achieved, the company is poised for international growth. Upadhyay envisions transforming India into a prominent technology and manufacturing hub, emphasizing the importance of homegrown innovation in the global marketplace.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sA9Brbe
via IFTTT

Read More

Aayush Wellness reports 10.6% rise in first-half income

Aayush Wellness experienced an increase in consolidated income and profit for the first half of fiscal 2027. The company reported an impressive rise in both consolidated income and profit after tax. Standalone income also showed significant growth compared to the preceding quarter. Aayush Wellness is launching new products to expand its presence in preventive healthcare and nutraceutical markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pvcVQ2H
via IFTTT

Read More

Govt plans instant ban on manufacturing of drugs failing key quality tests

Pharma companies could have their drug licenses suspended immediately if quality tests indicate failure. The health ministry's proposed changes aim to protect public health by enforcing swift action on substandard medications. Regulators would take action upon receiving a government analyst's report declaring a drug not of standard quality. Manufacturers would need to perform a root cause analysis and implement corrective actions to lift the suspension.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JWATw2S
via IFTTT

Read More

Inside Park Hospitals' regional playbook: Why North India depth matters more than national reach

Park Hospitals is on an ambitious expansion journey, targeting around 6,600 beds by December 2028 across North India. Their strategy focuses on building hospitals in close proximity for better operational efficiency. The new Prayagraj initiative underscores a successful public-private partnership and illustrates their commitment to enhance healthcare capacity, ultimately improving patient care and resource management in the region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XBV846w
via IFTTT

Read More

HRV Pharma buys Germany's Phatebo

The acquisition marks virtual pharmaceutical company HRV's entry beyond active pharmaceutical ingredients (APIs) into finished formulations, giving it its first finished formulations business alongside a licenced operating entity in Germany.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QKt3eqY
via IFTTT

Read More

NPPA updates list of reduced MRP of 1,085 anti-cancer drugs

The National Pharmaceutical Pricing Authority updated the maximum retail price for 1,085 anti-cancer medicines. This revision follows a previous decrease of prices for 543 anti-cancer drugs announced on October 28. The updated list contains prices based on information submitted by pharmaceutical companies up to November 3. The NPPA will continuously update this list as more manufacturers submit revised prices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Nwgr3iq
via IFTTT

Read More

Alkem Laboratories appoints Amrut Naik as CEO

Alkem Laboratories announced the appointment of Amrut Naik as its new Chief Executive Officer. His appointment is effective from November 11, following board approval and nomination committee recommendations. Naik has more than 26 years of experience in various areas, including pharmaceuticals and biologics. He holds both a bachelor's and master's degree in pharmaceutical science alongside a PhD in pharmacology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qhj5Lzp
via IFTTT

Read More

High Court restrains NPPA from action against AstraZeneca

The Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in effect until the next hearing date, January 11. AstraZeneca has argued that its product may not fall under controlled drug prices. The NPPA has accused AstraZeneca of overcharging for the inhaler from May 2016 to November 2025. AstraZeneca denies these allegations and claims compliance with the price regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/91SKhc4
via IFTTT

Read More

Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%

Wockhardt has expanded its marketing access for Miqnaf in India following the removal of a supply condition. The company's biotechnology sector recorded significant revenue growth, indicating strong demand for its products. Zaynich received US FDA approval for complicated urinary tract infections, serving as a milestone for Indian pharmaceuticals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hyKNisU
via IFTTT

Read More

Experts say health technology, preventive healthcare at inflection point, India ready to leverage

With a focus on preventive healthcare and wellness, India is on the verge of harnessing new technological innovations. Sangita Reddy from Apollo Hospitals stresses the significance of wearable devices in spotting health issues early on. In collaboration with Apollo Hospitals, Garmin Health is targeting rural health efforts and highlighting the event's health technology strides.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1BwDgi8
via IFTTT

Read More

India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs

Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth rate reached 12% year-on-year in the September quarter, showing a positive trend in the industry. Larger pharmaceutical companies have benefited from the shutdown of many non-compliant smaller units. Budgets were also boosted by a reduction in GST on medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ztCd01h
via IFTTT

Read More

India's first public sector proton beam therapy unit to come up in Assam; state signs MoU with Belgian firm

Assam has signed an MoU with Belgium-based Ion Beam Applications (IBA) to set up India's first public-sector proton beam therapy centre in Guwahati at a cost of Rs 600 crore. The facility will offer advanced cancer treatment, particularly for children, and is expected to take at least three years to become operational.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8QGNRKm
via IFTTT

Read More

Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are back

The government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicines covered in the 2019 exercise found that mark-ups had risen to as much as 700% by 2026, raising questions about whether one-time price cuts can keep cancer treatment affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lV5JvIn
via IFTTT

Read More

Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%

Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The transaction with Organon is expected to close in Q4 FY27.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lVIyPuW
via IFTTT

Read More

Omron Healthcare eyes Chennai as global manufacturing hub, targets 3 million BP monitors by 2028

Omron Healthcare has commenced full-scale production at its new facility near Chennai for blood pressure monitors. The company aims to produce three million monitors annually by 2028 for the Indian market. Initially, all produced devices will serve local consumers to address cardiovascular health challenges. Omron is also working towards increasing domestic sourcing of components to support local manufacturing initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2JSVslj
via IFTTT

Read More

NPPA list brings little relief: No price cut for 25% cancer drugs

Nearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across 643 packs is 38.22%. Several high-cost patented medicines remain unchanged, prompting patient advocates to question how much relief the trade-margin cap will actually deliver when the new prices take effect on November 9.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hqpvYDO
via IFTTT

Read More

India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: Pharmexcil

India's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driven by strong demand from Europe, ASEAN, and Latin America. Shipments included drug formulations, biologicals, bulk drugs, and surgical products. Exports to key regions, particularly Europe and ASEAN, rose significantly during this period. Industry leaders emphasized the need for India to enhance its pharmaceutical innovation and manufacturing capabilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1prYPNv
via IFTTT

Read More

Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini Piramal

In a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The company is actively diversifying its supply chains to provide greater flexibility against geopolitical challenges while broadening its manufacturing footprint to locations like India, the UK, and the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LhrKOSZ
via IFTTT

Read More